Decoy Therapeutics (NASDAQ:DCOY) Sees Large Decline in Short Interest

Decoy Therapeutics (NASDAQ:DCOY) was the recipient of a significant decrease in short interest during the month of August. As of August 14th, there was short interest totaling 10,675 shares, a decrease of 57.7% from the July 30th total of 25,246 shares. Based on an average daily trading volume, of 34,121 shares, the short-interest ratio is currently 0.3 days. Approximately 1.7% of the company’s stock are short sold.

Decoy Therapeutics Price Performance

Shares of NASDAQ:DCOY opened at $2.90 on Monday. The stock has a market capitalization of $1.91 million, a P/E ratio of -0.10 and a beta of 0.64. The business has a 50-day moving average of $4.93 and a two-hundred day moving average of $6.18. Decoy Therapeutics has a fifty-two week low of $2.85 and a fifty-two week high of $70.80.

Decoy Therapeutics (NASDAQ:DCOY) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($4.46) EPS for the quarter. The firm had revenue of $0.23 million during the quarter. As a group, research analysts expect that Decoy Therapeutics will post -12.97 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Decoy Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday, June 12th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $30.00.

About Decoy Therapeutics

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.